• Sulfo-Cy3 Azide in Neurodevelopmental Research

  2026-10-07

  A source-grounded overview of Sulfo-Cy3 azide as a fluorescent bioconjugation reagent, with emphasis on how conceptual labeling applications could relate to rat claustrum development research, what the published evidence actually shows, and where important limitations remain.

• From ZNF706 Signals to Translational qPCR Confidence

  2026-10-07

  ZNF706 is emerging as a compelling hepatocellular carcinoma biomarker, but its translational value depends on the analytical credibility of the RNA-to-qPCR measurement chain. This thought-leadership article examines how reverse-transcription design, evidence interpretation, and assay strategy can connect mechanistic cancer biology with more defensible biomarker development.

• MTT Beyond Viability: Interpreting Metabolic Signals

  2026-10-06

  MTT is more than a colorimetric cell viability assay reagent: its formazan signal is a context-dependent readout of cellular reducing activity. This article examines how to interpret MTT data alongside mitochondrial and inflammatory mechanisms, using recent PINK1/Parkin research as a case study.

• 2-NBDG: Principles, Evidence, and Limits

  2026-10-06

  A source-grounded overview of what 2-NBDG measures, how to interpret fluorescence-based glucose uptake results, and where evidence from cell and animal models does—and does not—support broader conclusions.

• Sulfo-Cy3 Azide in Translational Neuroimaging

  2026-10-05

  A source-grounded perspective on how Sulfo-Cy3 azide can connect developmental neurobiology, aqueous bioconjugation, and translational imaging while keeping evidence strength and applicability boundaries explicit.

• NMN, SIRT3, and Diabetic Myocardial Fibrosis

  2026-10-05

  A 2026 mouse study links nicotinamide mononucleotide with reduced diabetes-associated myocardial fibrosis and a proposed SIRT3–GSK3β–Smad3 signaling mechanism. The findings strengthen a testable preclinical framework for metabolic regulation research, but they do not establish definitive molecular causality or clinical efficacy.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-10-04

  A 2023 Cell Death & Disease study identifies an LMO2/LDB1 protein complex as a functional contributor to AML-cell maintenance, extending prior observations that LMO2 expression is associated with adverse disease biology. Using complementary cellular, proteomic, transcriptomic, chromatin, and in vivo evidence, the study supports LDB1 as a context-dependent regulatory dependency while leaving important questions about patient-level applicability unresolved.

• SGI-1027 and the Next Era of Cancer Epigenetics

  2026-10-03

  A thought-leadership perspective on SGI-1027 as a DNA methyltransferase inhibitor, connecting DNMT biology with rigorous phenotype interpretation, translational biomarker strategy, and the evidence boundaries that matter in cancer epigenetics research.

• Griseofulvin Microtubule Assay Workflows

  2026-10-02

  Griseofulvin is a practical microtubule associated inhibitor for connecting fungal growth phenotypes with mitotic mechanism. This workflow emphasizes solvent control, time-resolved phenotyping, and a cautious extension of a validated aneugen-mechanism assay into antifungal drug research.

• MRE11 K464R and Olaparib Resistance in HGSOC

  2026-10-01

  Zhuang et al. identified the MRE11:p.K464R mutation through cfDNA monitoring as a marker associated with acquired olaparib resistance in platinum-sensitive relapsed high-grade serous ovarian cancer. Their functional and mechanistic analyses suggest that the mutation strengthens MRE11 interactions with RAD50 and RPS3, promotes non-homologous end joining, and reduces drug-associated DNA damage.

• VER 155008: HSP 70 ATPase Biology

  2026-10-01

  VER 155008 is an adenosine-derived HSP 70 inhibitor for connecting ATPase-pocket engagement with apoptosis, cancer cell proliferation inhibition, and host-factor biology. This article explains how evidence from HSC70-dependent viral internalization can improve assay design without overstating translational conclusions.

• Hoechst 33342 for Nuclear Imaging Workflows

  2026-09-30

  Hoechst 33342 converts nuclear morphology and DNA content into practical readouts for live-cell imaging, cell cycle analysis, and apoptosis-oriented experiments. This workflow shows how to apply the dye to hypoxia pulmonary hypertension models, including endothelial cell–smooth muscle cell conditioned-medium assays, while avoiding common interpretation and staining errors.

• Trypsin-Responsive Nanomedicine for Acute Pancreatitis

  2026-09-30

  The ACS Nano study developed a mesoporous organosilica nanomedicine that combines pancreatic acinar-cell targeting, trypsin-triggered framework degradation, and intracellular calcium chelation. In a sodium taurocholate mouse model, the formulation reduced calcium overload and pancreatic injury while substantially improving survival, supporting a pathology-responsive strategy for acute pancreatitis treatment.

• Bradford Protein Assay Kit: Practical Protocol Guide

  2026-09-29

  The Bradford Protein Assay Kit (SKU K4103) provides a fast, low-volume method for protein concentration measurement in solution using Coomassie Brilliant Blue G-250 and absorbance at 595 nm. It is appropriate for routine enzyme, purification, and molecular biology workflows, but requires matrix validation when samples contain dye-binding interferents or when absolute protein purity is the objective.

• Bone Transport and TGF-β1 in Diabetic Foot Ulcer Repair

  2026-09-29

  A 2026 rat study shows that bone transport accelerates ischemic diabetic foot ulcer repair while activating TGF-β1/TGFBR1 signaling, angiogenesis, and immune regulation. Its multi-level design links wound-level remodeling with systemic responses and identifies TGF-β1-mediated osteo-immune coupling as a testable mechanism rather than treating improved healing as a purely mechanical effect.

8565 records 1/571 page Next 12345 下5页 Last page